Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
31.27
-1.35 (-4.14%)
At close: Aug 28, 2026, 4:00 PM EDT
30.76
-0.51 (-1.63%)
After-hours: Aug 28, 2026, 7:43 PM EDT
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $1.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.00M, down -93.33% year-over-year. In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth.
Revenue (ttm)
$1.00M
Revenue Growth
-93.33%
P/S Ratio
2,038.08
Revenue / Employee
$5,988
Employees
167
Market Cap
2.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ZBIO News
- 12 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley - TheFly
- 13 days ago - Zenas BioPharma reports Q2 EPS ($1.77), consensus (75c) - TheFly
- 13 days ago - Zenas BioPharma CFO Jennifer Fox to transition out of role - TheFly
- 14 days ago - Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley - TheFly
- 17 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 17 days ago - Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 17 days ago - Zenas BioPharma Earnings release: Q2 2026 - Filings